Regeneron Pharmaceuticals Inc
LSE:0R2M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
LSE:0R2M
|
US |
|
O
|
Oracle Corp
BMV:ORCL
|
US |
|
T
|
TechTarget Inc
SWB:EFT
|
US |
|
DaVita Inc
NYSE:DVA
|
US |
Wall St Price Targets
0R2M Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
0R2M is 847.58 USD with a low forecast of 647.83 USD and a high forecast of 1 050.68 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0R2M's stock price target?
Price Target
847.58
USD
According to Wall Street analysts, the average 1-year price target for
0R2M is 847.58 USD with a low forecast of 647.83 USD and a high forecast of 1 050.68 USD.
What is the Revenue forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
11%
Over the last 14 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 3 years is 11%.
What is the Gross Profit forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
13%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 27%. The projected CAGR for the next 3 years is 13%.
What is the Operating Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
23%
The compound annual growth rate for Operating Income over the next 3 years is 23%.
What is the Pre-Tax Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 15%.
What is the Net Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 3 years is 15%.